Trevi Therapeutics Inc (NASDAQ: TRVI) on Tuesday, plunged -0.31% from the previous trading day, before settling in for the closing price of $6.49. Within the past 52 weeks, TRVI’s price has moved between $2.30 and $7.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 7.03%. With a float of $59.67 million, this company’s outstanding shares have now reached $99.89 million.
Let’s determine the extent of company efficiency that accounts for 26 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Trevi Therapeutics Inc (TRVI) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Trevi Therapeutics Inc is 41.36%, while institutional ownership is 51.49%. The most recent insider transaction that took place on Mar 25 ’25, was worth 17,365. In this transaction Chief Scientific Officer of this company sold 2,631 shares at a rate of $6.60, taking the stock ownership to the 221,373 shares. Before that another transaction happened on Mar 21 ’25, when Company’s President & CEO sold 5,263 for $6.58, making the entire transaction worth $34,625. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 7.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.19% during the next five years compared to 27.09% growth over the previous five years of trading.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Trevi Therapeutics Inc (TRVI) is currently performing well based on its current performance indicators. A quick ratio of 15.38 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Looking closely at Trevi Therapeutics Inc (NASDAQ: TRVI), its last 5-days average volume was 1.13 million, which is a drop from its year-to-date volume of 1.75 million. As of the previous 9 days, the stock’s Stochastic %D was 35.27%. Additionally, its Average True Range was 0.41.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 76.52%, which indicates a significant increase from 31.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.50% in the past 14 days, which was lower than the 78.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.34, while its 200-day Moving Average is $4.17. However, in the short run, Trevi Therapeutics Inc’s stock first resistance to watch stands at $6.60. Second resistance stands at $6.72. The third major resistance level sits at $6.81. If the price goes on to break the first support level at $6.39, it is likely to go to the next support level at $6.30. Now, if the price goes above the second support level, the third support stands at $6.18.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
Market capitalization of the company is 658.29 million based on 99,893K outstanding shares. Right now, sales total 0 K and income totals -47,910 K. The company made 0 K in profit during its latest quarter, and -10,340 K in sales during its previous quarter.
